Top News
The biggest stories in mental health — FDA approvals, research, treatments, and policy — summarized plainly in our own words, with the original source linked on every card.
We’re gathering this week’s stories — the news desk has been quiet. The most recent stories we found are below.
Latest stories
Gathered every morning from sources like the FDA, NIMH, and the major psychiatry journals. On quiet days, we’d rather show you nothing new than pad the page.
Industry Lawsuits Challenge State Laws That Would Force Social Media Platforms to Warn Minors About Mental-Health Harms, With California's Version Due to Start January 1
Trade group NetChoice is suing California, Colorado and Minnesota over laws that would make platforms display a Surgeon General-style caution to young users — in California's case (AB 56, effective January 1) at first log-on, again after three hours of cumulative use, and at least hourly after that. The states argue the warnings are factual disclosures of the kind courts have long allowed for commercial speech, and 43 states plus Washington, D.C. have backed Colorado's law, while civil-liberties groups counter that forcing a platform to carry the government's view of its own speech is unconstitutional. A Colorado injunction is already on appeal, with arguments expected early next year.
Read at source ↗
Psychedelics' Hallucination-Like and Lasting Antidepressant-Like Effects Trace to Two Different Receptor Signals, Nature Neuroscience Study Finds
A Chinese Academy of Sciences and ShanghaiTech team mapped how psychedelics act on the serotonin 2A receptor and found the two effects appear to run on different clocks: a sharp peak in one signalling pathway lined up with hallucination-like behaviour in animals, while a second signal that builds up over time lined up with antidepressant-like effects that lasted. Guided by that split, the researchers built a compound that favours the second pathway; it eased depression-like behaviour in mice without detectable LSD-like responses in mice or monkeys, and repeated low doses of LSD itself showed the same build-up pattern. The work is preclinical only, but it offers drug designers two concrete routes toward treatments that might keep the benefit without the trip.
Read at source ↗
Comparing Yourself With Others on Social Media Tracked Teen Anxiety and Depression Signs More Strongly Than Scrolling to Pass Time in a 4,011-Student Norwegian Survey
Surveying 4,011 adolescents averaging about age 14 at 21 schools in southeastern Norway, researchers separated social media use into distinct behaviours — comparing oneself with others, passing time, seeking support, and giving or receiving hostility — and compared each with self-reported signs of depression, anxiety, social anxiety, attention difficulties and oppositional behaviour. Social comparison showed the strongest links across all five sign groups, while simply passing time, the most common use, was only weakly associated, suggesting total screen time lumps together experiences with very different meanings. Because everything was measured at once, the study in Child and Adolescent Psychiatry and Mental Health cannot say whether comparison fuels distress or distressed teens compare more; follow-up data from the same students is being collected.
Read at source ↗
Recorded Self-Harm Peaked Before ADHD Medication Was Started, Not After, in a Five-Database Study Covering 461,024 People
A self-controlled case series in BMJ Mental Health compared each person's self-harm timing against their own unexposed time, using health records from Hong Kong, New Zealand, South Korea, Taiwan and the UK covering 461,024 people prescribed ADHD medication, 6,847 of whom had a first recorded self-harm event. Relative incidence was highest in the 90 days before the first prescription (adjusted rate ratio 2.58 versus non-exposure), then lower during the first 90 days of use (1.78) and later use (1.27), though it stayed above baseline while on treatment. The authors conclude the pattern does not point to medication as the main driver — the circumstances and untreated symptoms that lead to a first prescription may explain much of the peak — and they advise monitoring and counselling both before and during treatment.
Read at source ↗
FDA-Cleared Personalised Brain Stimulation for PTSD Cut Symptoms by 52% in a 158-Person Sham-Controlled Trial, With 68% No Longer Meeting PTSD Criteria
Wave Neuroscience's MeRT system records a patient's brain activity with an EEG, uses an algorithm to tailor magnetic stimulation (TMS) to that individual pattern, and was cleared by the FDA in June 2026 for adults with PTSD; the trial findings behind the clearance were published on October 23. In the FDA-reviewed study, 158 adults received real or sham treatment over roughly five to six weeks of weekday sessions, and the developer reports an average 52% drop in symptom severity with 68% of treated patients no longer meeting PTSD criteria. How durable the benefit is, how it performs in broader populations, and how accessible the multi-week treatment will be all remain open questions.
Read at source ↗
Meta and Snap Go on Trial in Los Angeles Over Two Teenagers' Claims That Social Media Addiction Caused Their Depression, Anxiety and Eating Disorders
Two plaintiffs — a 16-year-old from Illinois and an 18-year-old from Mississippi — say features such as autoplay and endless scrolling pulled them into compulsive use from childhood and left them with depression, anxiety and eating disorders; TikTok and YouTube settled with them before trial, leaving Meta and Snap to face the jury. The case is only the second individual-plaintiff trial of its kind, after a March verdict that cost Meta and YouTube $6 million, and it serves as a bellwether for more than 3,000 similar lawsuits consolidated in Los Angeles, with Mark Zuckerberg, Adam Mosseri and Evan Spiegel expected to testify. Both companies deny designing their platforms to addict young users, and the judge has already ruled that Section 230 does not block claims aimed at platform design.
Read at source ↗
Teva Buys Worldwide Rights to BXCL501, an Under-the-Tongue Film for At-Home Agitation in Schizophrenia and Bipolar Disorder Now Under FDA Review
Teva said it has closed a court-supervised purchase of BioXcel Therapeutics' neuroscience assets for $57.5 million upfront plus up to $67.5 million in contingent payments, gaining worldwide rights to BXCL501 and to the already approved hospital-setting film IGALMI. BXCL501 is a dexmedetomidine film that dissolves under the tongue and is before the FDA as a supplemental application for treating acute agitation at home in adults with schizophrenia or bipolar I or II disorder, a problem Teva estimates touches 25% to 40% of people with those conditions. If regulators clear it, it would be the first approved option patients could use at home for such episodes, which today often end in an emergency visit or admission.
Read at source ↗
Olanzapine/Samidorphan Users Stayed on Treatment Longer and Had Fewer Hospital Admissions in Claims Analyses of 45,566 Adults With Schizophrenia
Two analyses presented at the AMCP Nexus 2026 meeting used Komodo Healthcare Map claims to compare the olanzapine/samidorphan combination with other oral second-generation antipsychotics and with olanzapine on its own. In the larger analysis of 45,566 adults with schizophrenia, people starting the combination remained on it for a mean of about 202 days versus roughly 132 to 174 days for comparators, were more likely to still be on treatment at 12 months, and showed higher adherence. A matched Medicaid comparison also linked the combination to fewer all-cause and mental-health hospital admissions in both schizophrenia and bipolar I disorder, though claims data can show association rather than prove the drug caused the difference.
Read at source ↗
Four-Day Concentrated Exposure Treatment Beat Eight Weeks of Online CBT for OCD in a 119-Person Randomised Trial, With the Gap Held at Three Months
A single-centre German trial randomised 119 adults with OCD to the Bergen four-day treatment — two preparatory sessions, then four days of intensive exposure and response prevention in small groups with one therapist per patient — or to an eight-week self-directed internet CBT programme. At three months the intensive group had cut its Yale-Brown scores by about 5.6 points more than the online group, with response in 61.4% versus 25% and remission in 42.1% versus 13.6%, and satisfaction was also higher. The JAMA Network Open authors suggest the two approaches may fit different steps of care rather than compete, while noting the trial was unblinded, at one centre, and followed patients only briefly.
Read at source ↗
Combined Brain Stimulation and Cognitive-Load Training Beat Either Alone in a 64-Person Trial of Adolescents With Major Depression
At a single centre in Shandong, China, 64 young people ages 11 to 18 with major depression were randomised to magnetic stimulation over the left prefrontal cortex, an eight-week programme of individually adjusted cognitive tasks such as story writing and positive imagery, both together, or sham stimulation with control training. The combined group finished with far lower self-rated depression scores than any other arm and reported the strongest lift in positive affect, while each single treatment still outperformed the control condition and no adverse events were recorded. Reporting the trial in BMC Psychiatry, the authors call the result preliminary and say larger studies with longer follow-up are needed to see whether the benefit holds.
Read at source ↗
Single Intranasal Dose of Mebufotenin Beat a Low-Dose Comparator on Depression Scores at Day 29 in a 193-Person Treatment-Resistant Depression Trial
In a randomised, double-blind phase 2b trial, 193 adults whose depression had not responded to earlier treatment received one nasal-spray dose of the short-acting psychedelic mebufotenin benzoate at 8 mg or 12 mg, or a 0.3 mg dose meant to stay below perception. By day 29 the higher doses had lowered standard depression rating scores by roughly five to six points more than the comparator, with response in about a third of participants against 12% on the low dose, and most people were ready to leave within two hours of dosing. Side effects were almost all mild or moderate, but many participants could guess which dose they had received, and the JAMA authors say phase 3 trials must confirm the finding.
Read at source ↗
Postpartum Recurrence Was 21% With Lithium Prophylaxis Versus 41% Without in a 10-Study Meta-Analysis in Bipolar Disorder
A systematic review in The Journal of Clinical Psychiatry pooled eight studies covering 554 women with bipolar I or II disorder who received preventive lithium around delivery, plus two further studies of what happened when lithium was stopped during pregnancy. Across the prophylaxis studies, about 21% of lithium-treated women had a postpartum recurrence compared with about 41% of untreated women, and preventive treatment most often began during pregnancy itself. The authors warn that the underlying literature is small and that women who stay on lithium may differ from those who do not, so the gap should be read as an association rather than a proven effect size.
Read at source ↗
Movie-Viewing Brain Scans Flagged Adolescent Depression With an AUC of 0.87 in a 200-Person Study, and Held Up in a Separate Cohort
Researchers trained an anomaly-detection model only on healthy teenagers' brain scans recorded while they watched movies, then used departures from that healthy pattern to pick out major depression among 200 adolescents, 112 of them with the diagnosis and 88 without, reaching an AUC of 0.87 and about 84% accuracy. The same cutoff carried over to a separate group of 138 adolescents with an AUC of 0.81, and the analysis pointed to muted emotional responding and rumination-like patterns across visual, default-mode and salience networks. Writing in npj Digital Medicine, the authors frame the approach as a step toward objective markers for adolescent depression, not a ready clinical test.
Read at source ↗
Deleting Neurexin Genes Reshaped Social Behaviour, Anxiety and Aggression in Zebrafish as They Matured, Molecular Psychiatry Study Finds
Griffith University researchers built zebrafish missing members of the neurexin gene family, a group strongly tied to psychiatric disorders, and found the fish developed and behaved normally early in life but showed marked, lasting changes in social behaviour, anxiety and aggression once they reached the juvenile stage. That delayed emergence mirrors the timing of several human conditions, and the team says the models let them trace brain-circuit changes before symptoms appear and screen for ways to prevent or reverse them. The work, published in Molecular Psychiatry, is a preclinical research platform rather than a finding in patients.
Read at source ↗
Weakened Beta-Band Brain Signal Tracked Sensory, Speech and Overall Symptoms in a 50-Person Schizophrenia Study
Using high-resolution magnetoencephalography in 25 people with schizophrenia and 25 healthy participants, McGill researchers found that beta-band brain activity was weaker and slower in the patient group while they judged the timing of sights and sounds. The size of that difference tracked with poorer sensory processing, more disorganized speech and more severe symptoms overall, which the team reads as a possible shared process sitting behind symptoms usually studied separately. With only 50 participants, the authors stress the signal is an early candidate marker that must be tested in larger groups before any clinical use.
Read at source ↗
1,260 Genetic Variants Linked to the Big Five Personality Traits in Analyses of Up to 1.14 Million People
Pooling 46 research groups, with samples ranging from about 611,000 to 1.14 million people depending on the trait, researchers identified 1,260 genetic variants tied to extraversion, agreeableness, conscientiousness, neuroticism or openness, most of them in regions not previously linked to the trait in question, in work published in Nature. Common variants together explained only about 5 to 9 percent of the differences in personality, and the pattern for neuroticism overlapped genetically with higher risk across the psychiatric conditions examined. The authors stress that these are group-level associations that cannot predict any one person's behaviour.
Read at source ↗
Higher Daily Fluid Intake Linked to Lower Post-Stroke Depression and Anxiety Symptoms in a 453-Person Cohort
A prospective cohort study in BMC Psychiatry followed 453 people recovering from ischemic stroke who were taking the sleep drug estazolam long term, averaging each person's daily liquid intake across the first six months after stroke and screening for symptoms at seven and twelve months. Higher intake went with a lower likelihood of screening positive for depressive or anxiety symptoms at both check-ins, and the association grew stronger step by step across intake levels. Because drinking was observed rather than assigned, the authors say only an interventional trial can show whether raising intake actually protects mood.
Read at source ↗
Depression and Suicidality Are the Most Reported Mental-Health Problems Among Adolescents Living With HIV in Sub-Saharan Africa, Review Finds
A scoping review in PLOS Global Public Health screened the recent literature down to 24 peer-reviewed studies of 10- to 19-year-olds living with HIV in sub-Saharan Africa. Six kinds of problems recurred across those studies — depression, generalized anxiety, suicidality, emotional and behavioural problems, posttraumatic stress and substance use — with depression and suicidality reported most often. The authors argue that routine mental-health screening and psychosocial support should be built into adolescent HIV care, while noting that a scoping review maps what evidence exists rather than measuring how well any intervention works.
Read at source ↗
Discrimination Tied to Higher Depression, Anxiety and Suicidal Thoughts in a Nearly 18,000-Student LGBTQ+ College Survey
Drawing on the 2024-2025 Healthy Minds Study, researchers analysed responses from 17,942 LGBTQ+ students ages 18 to 24 at 119 colleges and universities in 34 states, in work published in Behavioral Medicine and described as the largest study of its kind. About one in ten students reported discrimination on campus in the past year, and that group was 84% more likely to meet criteria for depression, 87% more likely to meet criteria for anxiety and 78% more likely to report suicidal thoughts. Students who had been denied health care faced a still higher burden, with a more than 200% higher likelihood of suicidal ideation, even though more than half of all participants had sought counselling.
Read at source ↗
Greece Parliament Approves Social Media Ban for Children Under 15, Taking Effect January 1, 2027
Greece's parliament has approved a law barring children under 15 from using social media platforms, citing growing concern about effects on minors' health and safety, with the ban due to start on January 1, 2027. Prime Minister Kyriakos Mitsotakis said platforms have about two and a half months to work out age verification that also protects privacy, and Greece is one of seven EU countries pursuing a shared verification approach with the European Commission. The government framed the move as support for parents against endless scrolling that cuts into sleep, concentration and time with friends, following Australia's earlier ban and a French law that was struck down in August.
Read at source ↗
Expert Panel: Network Meta-Analyses Support Earlier, Individualised Use of Adjunctive Antipsychotics When Depression Responds Poorly
Five psychiatry and psychopharmacology experts reviewed two recent network meta-analyses comparing the five FDA-approved atypical antipsychotics used as add-on treatment for adults whose major depression had not responded adequately to an antidepressant alone. Writing in The Journal of Clinical Psychiatry, the panel found the two analyses broadly agreed and said they can help clinicians weigh benefit against tolerability, patient characteristics and preferences, with earlier consideration of an approved add-on when it fits the patient. The panel endorsed no single drug and stressed that long-term, head-to-head and subgroup-specific evidence is still missing.
Read at source ↗
Childhood Brain Development Timeline Linked to Later Teen Depression and Anxiety in a Nearly 12,000-Person U.S. Study
Tracking nearly 12,000 U.S. children from about age nine, with roughly 30,000 brain scans taken every two years over six years, researchers charted how the cortex thins in an S-shaped pattern rather than at a steady pace, with sensory regions maturing ahead of areas for complex thought. Differences in that timing were tied to mental-health symptoms emerging up to four years later, and the regions involved overlapped with genes active before birth. The work, reported ahead of peer review, showed only subtle group-level patterns, so the authors and outside experts caution it cannot predict an individual child's future symptoms.
Read at source ↗
Personalised Brain Stimulation Guided by Each Patient's Own Circuits Shows Early Promise for Severe OCD
Clinicians at Singapore's National University Hospital and NUS Medicine completed a small study in four people with severe, treatment-resistant OCD using magnetic stimulation aimed not at a standard spot, but at a target refined from each person's own brain scan and from circuits where surgical stimulation is known to ease symptoms. The non-invasive sessions use a shorter stimulation form lasting about nine minutes, with repeated scans to watch circuits change during care. The team calls the early results encouraging and is now starting a larger, longer study in 30 people with depression and anxiety, running to early 2029.
Read at source ↗
Newron Completes Enrollment of 618 Patients in Pivotal Phase 3 Trial of Evenamide for Treatment-Resistant Schizophrenia
Newron Pharmaceuticals said it has finished enrolling its pivotal ENIGMA-TRS 1 study, randomising 618 people with treatment-resistant schizophrenia at more than 80 centres in 19 countries to receive its glutamate-modulating drug evenamide, at one of two doses, or placebo, added to their existing antipsychotic. The blinded study will report its main 12-week results in the first quarter of 2027 and continue for 52 weeks in total. If successful, evenamide could become the first add-on option developed specifically for this hard-to-treat group.
Read at source ↗
Radiomics Analysis of Brain Scans Showed Good Discrimination for Schizophrenia in a 14-Study Meta-Analysis
Pooling 14 studies that turned MRI and PET scans into large sets of quantitative features, researchers found those radiomics models separated schizophrenia-spectrum cases from others with a pooled AUC of 0.81, with sensitivity and specificity both around 0.74. Models also performed well when sorting treatment response, but results varied a lot between studies and outside validation was limited. The authors, publishing in Schizophrenia, say standardised methods and prospective testing are still needed before such tools could help in routine care.
Read at source ↗
NIH Funds Global Effort to Map Brain Function Across Eight Psychiatric Disorders Using More Than 94,000 Scans
A USC-led consortium will re-analyse resting-state brain scans from more than 94,000 people ages 4 to 95, gathered at 257 sites in 27 countries, under a five-year, $3.2 million grant funded by the National Institute of Mental Health. The work covers schizophrenia, bipolar disorder, major depression, PTSD, OCD, ADHD, autism and anorexia, all processed through one shared pipeline. By comparing the disorders side by side, the team hopes to separate brain patterns that are common across conditions from those that are distinctive, and to test whether brain function groups them in the same families that genetics suggests.
Read at source ↗
Healthier Diets Linked to Lower Depression Rates in Adults Over 70, Regardless of Genetic Risk
Deakin and Monash researchers followed 7,220 adults aged 70 and older for a median of 5.7 years and compared what they ate with later depressive symptoms, in a study published in Molecular Psychiatry. People eating four or more daily servings of ultra-processed food had a 12% higher rate of depressive symptoms, while those with more anti-inflammatory eating patterns had a 7% lower rate. The links held whether or not participants carried a higher genetic predisposition to depression or showed low-grade inflammation.
Read at source ↗
Researchers Identify a 'Circadian' Subtype of Depression Linked to Poorer Response to Common Antidepressants
Analyzing clinical and genetic data from more than 10,000 Australians with severe, recurrent or persistent depression, University of Sydney researchers found that 2,604 people — nearly one in four — fit a pattern tied to disruption of the body's 24-hour clock, marked by seasonal episodes, sleeping longer when depressed, waking unrefreshed and being a night owl. That group tended to develop depression earlier, report more severe symptoms, and carry higher genetic risk for inflammatory, cardiovascular and neurodevelopmental problems. Standard serotonin-based antidepressants worked less well and caused more side effects for them, which the authors say argues for considering clock-focused options such as melatonin-based medicines and light therapy earlier.
Read at source ↗
An Extra Daily Serving of Fruit Linked to Lower Depression and Anxiety Risk in a 6,537-Teen Study
Following 6,537 students at 71 Australian secondary schools from seventh to tenth grade, researchers found that each additional daily serving of fruit was linked to a 13% lower risk of later depression symptoms and a 7% lower risk of anxiety symptoms. Sugary drinks pointed the other way, with higher intake tied to a greater chance of both problems, a pattern that was especially strong for anxiety in boys. Published in Child and Adolescent Mental Health, the study started with teens who were not already showing elevated symptoms, so the diet patterns came before the symptoms that emerged.
Read at source ↗
ADHD Linked to 71% Higher All-Cause Mortality in a 19-Study JAMA Network Open Meta-Analysis, With Medication Linked to Lower Risk
Pooling 19 longitudinal studies covering more than 15.9 million people, researchers found that ADHD was associated with a 71% higher hazard of death from any cause, alongside higher hazards for suicide, for intentional or unintentional injury, and for natural causes such as cardiovascular and metabolic disease. In the smaller set of studies that looked at treatment, ADHD medication use was associated with a 25% lower all-cause mortality hazard. The authors stress that the underlying studies varied widely and were observational, so the medication finding is an association to test further rather than proof of a protective effect.
Read at source ↗
Rapport's RAP-219 Meets Its Main Goal in a Phase 2 Trial for Acute Bipolar Mania
Rapport Therapeutics reported that its experimental drug RAP-219 beat placebo in a Phase 2 study of adults in an acute manic episode of bipolar I disorder, lowering mania rating scores by an extra 3.1 points at week 3 and also meeting a global mania-severity endpoint. Every reported side effect was mild or moderate, overall rates were close to placebo, and no severe or serious adverse events occurred during treatment. The company plans an FDA meeting in early 2027 and expects to start Phase 3 trials in the second half of 2027.
Read at source ↗
One Session of Focused Brain Ultrasound Eased Delusions in a Small Early Schizophrenia Study
NYU Langone researchers tested transcranial ultrasound stimulation — focused sound waves aimed at a deep brain region involved in psychosis circuits — in 10 people with schizophrenia or schizoaffective disorder whose symptoms had persisted despite medication. After a single real 10-minute session, delusion severity scores dropped by an average of 1.2 points, while scores edged up after a sham session, and side effects such as fatigue and headache were mild and short-lived. Published in npj Acoustics, the results are preliminary and from a very small group, so larger studies will be needed to judge whether the benefit lasts.
Read at source ↗
More Than Half of British Columbia Youth Ages 10 to 24 Had a Mental-Health Care Contact Over 15 Years, BMC Psychiatry Study Finds
Following provincial health records for 597,273 British Columbia residents ages 10 to 24 from 2008 to 2022, researchers found that 52.4% had at least one new care contact for one of five mental-disorder groups. Mood and anxiety problems were the most common reason and usually appeared on their own, while conduct, substance-use, and psychotic disorders more often showed up in combination. New contacts climbed across the 15 years even after accounting for age and sex, which the authors read as rising demand that services will need to plan for.
Read at source ↗
Inactivity and Poor Sleep Strongly Tracked Teen Depression, Anxiety and Stress in a 45,922-Student Fujian Study
Surveying 45,922 secondary-school students ages 12 to 19 in six Fujian cities, researchers found symptoms of depression in 18.9%, anxiety in 22.0%, and stress in 9.2%. Students who were not regularly active had nearly double the odds of depression, and daytime impairment tied to poor sleep was the single strongest sleep-related marker, linked to more than four times the odds of stress. The authors point to school and family efforts around regular activity and healthier sleep as practical prevention targets.
Read at source ↗
Disrupted Eating Rhythms Independently Linked to Mixed Features in a 294-Patient Depression Study
Across four hospitals in China, 294 people in a major depressive episode were assessed for mixed features and for how far their daily sleep, social, activity, and eating rhythms had drifted. Nearly 62% had mixed features, and that group showed more disruption across sleep, social, and eating rhythms; after adjustment, each step up in eating-rhythm disruption came with 14% higher odds of mixed features. Because the study was cross-sectional, the authors say it cannot show whether irregular rhythms help trigger mixed states or result from them.
Read at source ↗
Psilocybin COMP360 Benefit Held Through 26 Weeks in Phase 3 Treatment-Resistant Depression Studies
Encore analyses from Compass Pathways' two pivotal phase 3 studies found that the share of participants with a clinically meaningful drop in depressive symptoms at week 6 — 25% after a 25 mg dose in one study and 39% after two fixed 25-mg doses in the other — held that benefit on average through at least week 26, with no new safety findings. Some participants who had improved without reaching remission got there after an additional dose. Companion real-world analyses found the costs and care use of treatment-resistant depression concentrated during resistant episodes, which the company argues makes durability of response especially valuable.
Read at source ↗
Depression or Anxiety Was the Most Common First Recorded Diagnosis Before Schizophrenia in a 21,590-Patient Japanese Claims Study
Reviewing nationwide Japanese insurance claims for 21,590 people with a first recorded schizophrenia diagnosis, researchers found that about three in four had an earlier psychiatric diagnosis on file, most often a depressive episode (45.2%) or an anxiety disorder (21.6%). When that first diagnosis was something other than schizophrenia, it came about 20 months before the schizophrenia diagnosis on average. Patients with prior diagnoses had a slightly lower adjusted risk of later psychiatric admission but a higher risk of physician-certified sick leave, and the authors say the long lead time argues for continued reassessment as mood and anxiety presentations evolve.
Read at source ↗
After High Suicide-Risk Flags Were Lifted, Veterans Who Later Died Showed Sharp Drops in Care Engagement, Record-Language Study Finds
Using natural language processing on VA health records, researchers compared 89 veterans whose high-suicide-risk classification had been removed before they died by suicide within six months with 89 veterans whose high-risk status stayed in place until death. The declassified group's notes carried more psychotherapy-oriented language, and after the flag was lifted their documented engagement fell sharply across care topics, while the comparison group's engagement held steady or increased. The authors caution that the work is exploratory and VA-specific, but suggest that apparent improvement can mask vulnerability when monitoring is stepped down.
Read at source ↗
FDA Clears First Treatment Aimed at Schizophrenia's Negative Symptoms — and It's an App
The FDA has cleared Motivista, a prescription smartphone app used alongside clinician-managed care, for the negative symptoms of schizophrenia — the loss of motivation and pleasure that standard medication has never specifically targeted. Our full story covers what the trial showed, and what it didn't.
Read story →
Stanford Psychiatrist Karl Deisseroth Wins the 2026 Nobel Prize
A practicing psychiatrist has won medicine's top honor for optogenetics, the technique he pioneered for switching specific brain cells on and off with light. The work is reshaping how scientists study depression, schizophrenia, and the brain itself.
Read story →